tiprankstipranks
Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
PremiumCompany AnnouncementsDenali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
1M ago
Denali Therapeutics reinstated with a Market Perform at Raymond James
Premium
The Fly
Denali Therapeutics reinstated with a Market Perform at Raymond James
1M ago
Denali Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Denali Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
2M ago
Denali Therapeutics reports Q2 EPS (59c), consensus (67c)
PremiumThe FlyDenali Therapeutics reports Q2 EPS (59c), consensus (67c)
4M ago
Denali Therapeutics management to meet with Oppenheimer
Premium
The Fly
Denali Therapeutics management to meet with Oppenheimer
4M ago
Denali Therapeutics price target raised to $29 from $28 at JPMorgan
Premium
The Fly
Denali Therapeutics price target raised to $29 from $28 at JPMorgan
5M ago
Denali completes enrollment for Regimen G of Phase 2/3 HEALEY ALS trial
PremiumThe FlyDenali completes enrollment for Regimen G of Phase 2/3 HEALEY ALS trial
7M ago
Denali Therapeutics price target lowered to $32 from $70 at UBS
Premium
The Fly
Denali Therapeutics price target lowered to $32 from $70 at UBS
8M ago
Denali Therapeutics files to sell 29.29M shares of common stock for holders
Premium
The Fly
Denali Therapeutics files to sell 29.29M shares of common stock for holders
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100